Q-omics provides the consensus-scored SMIM12 profile across patient tissues and cancer cell-line models. SMIM12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMIM12 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SMIM12 RNA expression shows 18,798 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where SMIM12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM12 survival associations across molecular data types. SMIM12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM12 RNA expression–survival associations across cancer types. High SMIM12 expression shows unfavorable associations in ACC, KICH, LGG, LIHC and UCS, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMIM12 RNA expression.
This table summarizes SMIM12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMIM12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM12 shows lower tumor expression in KICH, LUAD and KIRC and higher tumor expression in HNSC, STAD and ESCA. The HNSC box plot shows higher SMIM12 RNA expression in tumor versus normal tissue (log2 FC = +0.384, t-test p < 0.001).
This table shows molecular features associated with SMIM12 in patient tissues and cancer cell lines. In patient samples, SMIM12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
